Combined Cytoreductive Surgery and Early Postoperative Intraperitoneal Chemotherapy for XXXX of @entity356 .

@entity1 @entity298 @entity5 @entity3 @entity356
PURPOSE: Peritoneal seeding is the most common type of @entity3 or recurrence and one of the poor prognostic factors in @entity356 . Moreover, there are as yet no effective treatment modalities available. Recently some research groups suggested the benefit of combined cytoreductive surgery and intraperitoneal chemotherapy, but the related experiments remain in the trial stage. Therefore, we assessed the safety and evaluated the efficacy of combined cytoreductive surgery and early postoperative intraperitoneal chemotherapy (EPIC) in @entity356 @entity1 with @entity298 of @entity356 . MATERIALS AND METHODS: From Nov. 1997 to May. 2002, eighteen cases of combined cytoreduction and EPIC were performed in the @entity5 Center Hospital due to @entity356 with @entity298 . The control group consisted of 33 @entity1 who had no resection without EPIC during the same periods. After combined cytoreductive surgery and EPIC, all @entity1 received systemic chemotheraphy with the exception of 2 @entity1 who could not tolerate the treatment. We retrospectively investigated the clinicopathologic features and analyzed the factors affecting the prognosis. Median follow-up period was 11.9 months (range 0.5~61 months). Statistical analysis was performed by SPSS 11.0 for Windows. A P-value less than 0.05 was considered as statistically significant. RESULTS: There was one case of the treatment-related mortality (5.5%) and seven cases of treatment-related complications (38%) in the combined cytoreductive surgery and intraperitoneal chemotherapy group. One-, 3- and 5-year survival rates of cytoreductive surgery plus EPIC were 57.6%, 25.9% and 13.0%, respectively, and those of the control group were 18.2%, 3% and 0%, respectively. Survival of the combined cytoreductive surgery plus EPIC group was better than that of the control group (p=0.0026). In multivariate analysis of prognostic factors affecting the survival, combined cytoreductive surgery plus EPIC (p=0.02) and systemic chemotherapy (p=0.019) were independent prognostic factors. CONCLUSION: Although a small number of cases were included in this study, combined cytoreductive surgery plus EPIC showed survival benefit and retained a comparable complication rate compared with the control group.
